This site is intended for healthcare professionals

Bavarian Nordic enters first larger vaccine contract with government in response to monkey pox outbreak.

Read time: 1 mins
Published:31st May 2022

Bavarian Nordic A/S announced the signing of a supply contract with an undisclosed country for the Company’s smallpox vaccine with the aim to ensure sufficient supply to meet the country’s requirements for vaccinating individuals at risk for monkeypox in the short to medium term.

The vaccine is approved for use against monkeypox by the FDA and Health Canada as the only vaccine having obtained regulatory approval for this indication in any territory.

While the terms of the agreement remain undisclosed, the order will positively impact the Company’s financial guidance for 2022

Bavarian Nordic is currently in dialogue with several other governments concerning supply of the vaccine to mitigate the current monkeypox outbreak and to explore opportunities for longer term collaboration to build stockpiles for future preparedness. Officially, monkeypox cases have been reported in more than 15 countries as of to-date with numbers continuing to rise. In this unprecedented situation, the Company is making every possible effort to ensure sufficient availability of vaccines to meet the current demand.

Condition: Monkeypox + Orthopoxvirus Infections
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.